Polar Capital Biotech I Inc
SpecialistPricing frequency
Daily
Dealing cut off time
13:45
Type
OEIC
Yield
–
NAV
$73.35
Income frequency
Annually
Ongoing charge
1.1%
Latest actual NAV date
02-10-2026
ISIN
IE00B42Z4531
UCITS
Yes
This fund can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Before investing please read:
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 31/08/2026 | % of assets |
|---|---|
| Amgen Inc | 4.86 |
| Madrigal Pharmaceuticals Inc | 4.47 |
| argenx SE | 4.40 |
| Insmed Inc | 4.12 |
| Alnylam Pharmaceuticals Inc | 4.07 |
| Rhythm Pharmaceuticals Inc | 4.05 |
| Xenon Pharmaceuticals Inc | 3.91 |
| Ascendis Pharma AS | 3.65 |
| Arcutis Biotherapeutics Inc Ordinary Shares | 3.57 |
| Enliven Therapeutics Inc | 3.55 |
Investment objective
The investment objective of the Fund is to achieve long term capital appreciation. The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of biotechnology, diagnostics and life sciences tools companies.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.